ENZA-p: A randomised phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide.

  • Voskoboynik, Mark (Primary Chief Investigator (PCI))
  • Hawkins, Cheryl-Ann (Project Manager)

Project: Research

Project Details

StatusActive
Effective start/end date22/09/20 → 31/12/25

Keywords

  • Medical Oncology
  • Prostrate Cancer
  • Clinical trial